Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q2 FY20 results · Jul–Sep 2019
Suven Life Sciences reported revenue from operations of ₹274.31 crore and net profit of ₹63.31 crore for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 274.31 | — | — | 198.99 | +37.9% |
| Other income | 5.59 | — | — | 3.01 | +85.8% |
| Total income | 279.90 | — | — | 201.99 | +38.6% |
| Profit before tax | 99.66 | — | — | 55.21 | +80.5% |
| Net profit for the period | 63.31 | — | — | 26.21 | +141.6% |
| EPS, basic (₹) | 4.97 | — | — | 2.06 | +141.3% |
| Net margin (%) | 23.1 | — | 13.2 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 274.31 | 89.52 | +206.4% | 198.99 | +37.9% |
| Other income | 5.59 | 6.59 | −15.2% | 3.01 | +85.8% |
| Total income | 279.90 | 96.11 | +191.2% | 201.99 | +38.6% |
| Profit before tax | 108.67 | 24.85 | +337.3% | 86.18 | +26.1% |
| Net profit for the period | 72.32 | 18.01 | +301.6% | 57.18 | +26.5% |
| EPS, basic (₹) | 5.68 | 1.41 | +302.8% | 4.49 | +26.5% |
| Net margin (%) | 26.4 | 20.1 | 28.7 |
Consolidated
- Filed with BSE
- 14 Nov 2019, 17:36 IST
- Board meeting
- 14 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Nov 2019, 17:36 IST
- Board meeting
- 14 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE